What Happened?
Cambridge, MA-based Cerevel Resigned Mark Bodenrader as Interim Chief Financial Officer
About the Company
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson`s, Alzheimer`s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
About the Person
Mark Bodenrader is Interim Chief Financial Officer at Cerevel. Previously, Mark held various senior HR leadership roles in the industry.
Info Source
News
Short Profile